Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab in Diabetic Painful Neuropathy
NCT00993018Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Nov 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulranumab in diabetic peripheral neuropathy (DPN) (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Average pain intensity score. Started Nov 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00993018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00993018.